In vitro characterisation of the duration of action of the histamine-1 receptor antagonist azelastine
In vitro characterisation of the duration of action of the histamine-1 receptor antagonist azelastine
Azelastine is a selective antagonist at the human histamine-1 receptor and is used clinically in the treatment of allergic rhinitis. In this study we have investigated its duration of action in vitro in an effort to characterise the receptor and tissue components involved. Chinese hamster ovary cell membrane fragments were used to determine the kinetics of azelastine at the H1 receptor in a radioligand binding assay. Further duration of action studies were completed in tissue preparations using guinea-pig trachea and human bronchus. In radioligand binding studies, azelastine reached steady state at the H1 receptor after approximately 41 min and exhibited a significantly slower dissociation rate constant from the receptor than the first generation antihistamine, diphenhydramine. In washout studies completed in guinea-pig and human airway in vitro tissue preparations, azelastine continued to antagonise the effects of histamine at the H1 receptor for at least 18 h post-washout of the antagonist. This outcome was reversed following removal of the epithelium from guinea-pig isolated tracheal strips. These studies indicate there is a tissue component contributing to azelastine's duration of action, in addition to its direct H1 receptor binding, with evidence suggesting a role for the epithelial layer.
allergic rhinitis, zelastine, duration of action, epithelium, histamine-1 receptor, histamine antagonist
586-592
Slack, Robert J.
ecb80405-9ad4-46b2-b2a8-813a82dc2981
Hart, Adam D.
e5aa7d8f-47a2-408a-a9c9-fce7df90bdca
30 November 2011
Slack, Robert J.
ecb80405-9ad4-46b2-b2a8-813a82dc2981
Hart, Adam D.
e5aa7d8f-47a2-408a-a9c9-fce7df90bdca
Slack, Robert J. and Hart, Adam D.
(2011)
In vitro characterisation of the duration of action of the histamine-1 receptor antagonist azelastine.
European Journal of Pharmacology, 670 (2-3), .
(doi:10.1016/j.ejphar.2011.09.017).
(PMID:21946109)
Abstract
Azelastine is a selective antagonist at the human histamine-1 receptor and is used clinically in the treatment of allergic rhinitis. In this study we have investigated its duration of action in vitro in an effort to characterise the receptor and tissue components involved. Chinese hamster ovary cell membrane fragments were used to determine the kinetics of azelastine at the H1 receptor in a radioligand binding assay. Further duration of action studies were completed in tissue preparations using guinea-pig trachea and human bronchus. In radioligand binding studies, azelastine reached steady state at the H1 receptor after approximately 41 min and exhibited a significantly slower dissociation rate constant from the receptor than the first generation antihistamine, diphenhydramine. In washout studies completed in guinea-pig and human airway in vitro tissue preparations, azelastine continued to antagonise the effects of histamine at the H1 receptor for at least 18 h post-washout of the antagonist. This outcome was reversed following removal of the epithelium from guinea-pig isolated tracheal strips. These studies indicate there is a tissue component contributing to azelastine's duration of action, in addition to its direct H1 receptor binding, with evidence suggesting a role for the epithelial layer.
This record has no associated files available for download.
More information
Published date: 30 November 2011
Keywords:
allergic rhinitis, zelastine, duration of action, epithelium, histamine-1 receptor, histamine antagonist
Organisations:
Centre for Biological Sciences
Identifiers
Local EPrints ID: 344346
URI: http://eprints.soton.ac.uk/id/eprint/344346
ISSN: 0014-2999
PURE UUID: 03fc4d37-e7a9-4fb7-bf33-c195dcc90f2c
Catalogue record
Date deposited: 18 Oct 2012 10:57
Last modified: 14 Mar 2024 12:12
Export record
Altmetrics
Contributors
Author:
Robert J. Slack
Author:
Adam D. Hart
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics